Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma
Abstract Hepatocellular carcinoma is a common type of cancer associated with a high mortality rate. Among several bioactive compounds, Murrayafoline A (MuA) has been proved as a bio substance that exhibits great potentials in treating liver cancer. In order to overcome the high cytotoxicity and low...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2022-10-01
|
| Series: | Journal of Materials Science: Materials in Medicine |
| Online Access: | https://doi.org/10.1007/s10856-022-06692-1 |
| _version_ | 1811194827056873472 |
|---|---|
| author | Cuc Thi Dinh Ha Thi Vu Quynh Thi Huong Phan Linh Phuong Nguyen Toan Quoc Tran Dung Van Tran Nguyen Ngoc Quy Dung Thuy Nguyen Pham Duong Thanh Nguyen |
| author_facet | Cuc Thi Dinh Ha Thi Vu Quynh Thi Huong Phan Linh Phuong Nguyen Toan Quoc Tran Dung Van Tran Nguyen Ngoc Quy Dung Thuy Nguyen Pham Duong Thanh Nguyen |
| author_sort | Cuc Thi Dinh |
| collection | DOAJ |
| description | Abstract Hepatocellular carcinoma is a common type of cancer associated with a high mortality rate. Among several bioactive compounds, Murrayafoline A (MuA) has been proved as a bio substance that exhibits great potentials in treating liver cancer. In order to overcome the high cytotoxicity and low solubility of MuA, a delivery system based on nanocarriers is necessary to deliver MuA towards the desired target. In the present study, 18β-glycyrrhetinic acid (GA), which is known as a ligand for liver targeting, was used to construct the cholesterol-poly (ethylene glycol)-glycyrrhetinic acid (GA-PEG-Chol) conjugate and liposome for MuA administration. The compound was then examined for therapeutic efficacy and safety in HUVEC and HepG2 cells in 2D and 3D cell cultures. Results have shown that MuA-loaded liposomes had IC50 value of 2 µM in HepG2 and had the cytosolic absorption of 8.83 ± 0.97 ng/105 cells, while The IC50 value of MuA-loaded liposomes in HUVEC cell lines was 15 µM and the the cytosolic absorption was recorded as 3.62 ± 0.61 cells. The drug test on the 3D cancer sphere platform of the HepG2 cancer sphere showed that MuA-loaded GA liposomes had the highest efficacy at a concentration of 100 µg/mL. In short, these results suggest that MuA-loaded GA liposomes have the potential for maintenance drug delivery and liver targeting. |
| first_indexed | 2024-04-12T00:33:07Z |
| format | Article |
| id | doaj.art-5fc424074609474fb7c962f30041f306 |
| institution | Directory Open Access Journal |
| issn | 1573-4838 |
| language | English |
| last_indexed | 2024-04-12T00:33:07Z |
| publishDate | 2022-10-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Materials Science: Materials in Medicine |
| spelling | doaj.art-5fc424074609474fb7c962f30041f3062022-12-22T03:55:15ZengSpringerJournal of Materials Science: Materials in Medicine1573-48382022-10-01331011410.1007/s10856-022-06692-1Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinomaCuc Thi Dinh0Ha Thi Vu1Quynh Thi Huong Phan2Linh Phuong Nguyen3Toan Quoc Tran4Dung Van Tran5Nguyen Ngoc Quy6Dung Thuy Nguyen Pham7Duong Thanh Nguyen8Institute of Chemistry, Vietnam Academy of Science and Technology (VAST)Institute of Natural Products ChemistryInstitute of Chemistry, Vietnam Academy of Science and Technology (VAST)Hanoi Medical UniversityInstitute of Natural Products ChemistryVIET ANH VENTURE INVESTMENT J.S. COMPANY USA SANFORDPHARMA FACTORYInstitute of Applied Technology and Sustainable Development, Nguyen Tat Thanh UniversityInstitute of Applied Technology and Sustainable Development, Nguyen Tat Thanh UniversityInstitute of Chemistry, Vietnam Academy of Science and Technology (VAST)Abstract Hepatocellular carcinoma is a common type of cancer associated with a high mortality rate. Among several bioactive compounds, Murrayafoline A (MuA) has been proved as a bio substance that exhibits great potentials in treating liver cancer. In order to overcome the high cytotoxicity and low solubility of MuA, a delivery system based on nanocarriers is necessary to deliver MuA towards the desired target. In the present study, 18β-glycyrrhetinic acid (GA), which is known as a ligand for liver targeting, was used to construct the cholesterol-poly (ethylene glycol)-glycyrrhetinic acid (GA-PEG-Chol) conjugate and liposome for MuA administration. The compound was then examined for therapeutic efficacy and safety in HUVEC and HepG2 cells in 2D and 3D cell cultures. Results have shown that MuA-loaded liposomes had IC50 value of 2 µM in HepG2 and had the cytosolic absorption of 8.83 ± 0.97 ng/105 cells, while The IC50 value of MuA-loaded liposomes in HUVEC cell lines was 15 µM and the the cytosolic absorption was recorded as 3.62 ± 0.61 cells. The drug test on the 3D cancer sphere platform of the HepG2 cancer sphere showed that MuA-loaded GA liposomes had the highest efficacy at a concentration of 100 µg/mL. In short, these results suggest that MuA-loaded GA liposomes have the potential for maintenance drug delivery and liver targeting.https://doi.org/10.1007/s10856-022-06692-1 |
| spellingShingle | Cuc Thi Dinh Ha Thi Vu Quynh Thi Huong Phan Linh Phuong Nguyen Toan Quoc Tran Dung Van Tran Nguyen Ngoc Quy Dung Thuy Nguyen Pham Duong Thanh Nguyen Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma Journal of Materials Science: Materials in Medicine |
| title | Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma |
| title_full | Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma |
| title_fullStr | Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma |
| title_full_unstemmed | Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma |
| title_short | Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma |
| title_sort | synthesis of glycyrrhetinic acid modified liposomes to deliver murrayafoline a for treatment of hepatocellular carcinoma |
| url | https://doi.org/10.1007/s10856-022-06692-1 |
| work_keys_str_mv | AT cucthidinh synthesisofglycyrrhetinicacidmodifiedliposomestodelivermurrayafolineafortreatmentofhepatocellularcarcinoma AT hathivu synthesisofglycyrrhetinicacidmodifiedliposomestodelivermurrayafolineafortreatmentofhepatocellularcarcinoma AT quynhthihuongphan synthesisofglycyrrhetinicacidmodifiedliposomestodelivermurrayafolineafortreatmentofhepatocellularcarcinoma AT linhphuongnguyen synthesisofglycyrrhetinicacidmodifiedliposomestodelivermurrayafolineafortreatmentofhepatocellularcarcinoma AT toanquoctran synthesisofglycyrrhetinicacidmodifiedliposomestodelivermurrayafolineafortreatmentofhepatocellularcarcinoma AT dungvantran synthesisofglycyrrhetinicacidmodifiedliposomestodelivermurrayafolineafortreatmentofhepatocellularcarcinoma AT nguyenngocquy synthesisofglycyrrhetinicacidmodifiedliposomestodelivermurrayafolineafortreatmentofhepatocellularcarcinoma AT dungthuynguyenpham synthesisofglycyrrhetinicacidmodifiedliposomestodelivermurrayafolineafortreatmentofhepatocellularcarcinoma AT duongthanhnguyen synthesisofglycyrrhetinicacidmodifiedliposomestodelivermurrayafolineafortreatmentofhepatocellularcarcinoma |